Keros Therapeutics, Inc.
KROS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$7,280 | -$30,696 | $148,451 | -$46,026 |
| Dep. & Amort. | $395 | $370 | $344 | $332 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $3,986 | $8,542 | $8,863 | $9,200 |
| Change in WC | $5,539 | -$8,420 | $2,929 | -$10,086 |
| Other Non-Cash | $609 | $581 | $584 | $572 |
| Operating Cash Flow | $3,249 | -$29,623 | $161,171 | -$46,008 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$132 | -$720 | -$565 | -$289 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $0 | $0 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$132 | -$720 | -$565 | -$289 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $138 | $17 | $4 | $73,099 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $2 | $0 | $0 | $2,445 |
| Financing Cash Flow | $140 | $17 | $4 | $75,544 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $3,257 | -$30,326 | $160,610 | $29,247 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $691,664 | $721,990 | $561,380 | $532,133 |
| End Cash | $694,921 | $691,664 | $721,990 | $561,380 |
| Free Cash Flow | $3,117 | -$30,343 | $160,606 | -$46,297 |